Navigating the landscape of targeted therapies for renal cell carcinoma in the era of precision medicine (Review).
Emerging biomarkers help doctors better match kidney cancer patients with targeted therapies most likely to work for their specific tumors.
This phase iii clinical trial examined Navigating the landscape of targeted therapies for renal cell carcinoma in the era of precision medicine (Review). The PubMed abstract reports that Emerging biomarkers, including International Metastatic Renal Cell Carcinoma Database Consortium risk stratification, programmed death‑ligand 1 expression and chromatin remodeling gene alterations (polybromo 1/BRG1‑associated factor 180, BRCA1‑associated protein 1 and SET domain containing 2), are discussed in the context of their clinical utility and limita.
What the study was
- Study design
- Phase III clinical trial
- Population
- Human participants
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- Molecular medicine reports
Why it surfaced
Score 7/10 reflects phase iii clinical trial evidence with abstract only access; genuine match to Precision oncology and genomic medicine.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.